Metsera (NASDAQ:MTSR) Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Metsera (NASDAQ:MTSR) from a sell rating to a hold rating in a research note published on Wednesday.

Several other equities analysts have also recently issued reports on MTSR. Wells Fargo & Company cut Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price objective on the stock. in a research note on Tuesday. Leerink Partners restated a “market perform” rating and set a $57.00 price objective (down from $77.00) on shares of Metsera in a research note on Wednesday, September 24th. Bank of America increased their target price on Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Guggenheim increased their target price on Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, June 10th. Finally, Leerink Partnrs lowered Metsera from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $55.75.

Metsera Stock Performance

Shares of MTSR opened at $51.90 on Wednesday. The business’s fifty day moving average price is $37.66 and its 200 day moving average price is $30.93. Metsera has a 12-month low of $12.30 and a 12-month high of $54.47.

Metsera (NASDAQ:MTSR) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Metsera

Several large investors have recently added to or reduced their stakes in the stock. Alphabet Inc. acquired a new stake in Metsera in the first quarter worth $135,059,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Metsera during the first quarter valued at $78,748,000. Wellington Management Group LLP acquired a new position in shares of Metsera during the first quarter valued at $65,382,000. Alpha Wave Global LP acquired a new position in shares of Metsera during the first quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Metsera during the first quarter valued at $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.